ProtoKinetix

ProtoKinetix Net Debt/Equity

The Net Debt to Equity Ratio of ProtoKinetix (PKTX) as of Nov 19, 2026 is -0.55. In the previous year, Net Debt to Equity Ratio was -0.50 — a change of 11.49% (lower).

Net Debt/Equity

-0.55

YoY

11.49%

Last updated:

Net Debt to Equity Ratio of ProtoKinetix is 2018 -0.55 . Net Debt to Equity Ratio of ProtoKinetix was 2017 -0.50 . It decreases by 11.49% lower compared to the previous year.

The ProtoKinetix Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2014
-0.38 USD
Jan 1, 2015
-0.92 USD
Jan 1, 2016
-0.75 USD
Jan 1, 2017
-0.50 USD
Jan 1, 2018
-0.55 USD
The ProtoKinetix Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.55+11.49%
-0.50-33.58%
-0.75-18.62%
-0.92+141.24%
-0.38—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Net Debt to Equity Ratio of ProtoKinetix is -0.55 in 2018.

Net Debt to Equity Ratio of ProtoKinetix changed from -0.50 to -0.55, representing a 11.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ProtoKinetix

All Key Metrics — ProtoKinetix